

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

\_\_\_\_\_  
Type or print name of person signing certification

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: Arindam Chatterjee

Group Art Unit: 4161

Serial No.: 10/535,061

Examiner:  
Valerie Rodriguez-Garcia

Filing Date: May 12, 2005

Conf No.: 9394

For: Mixed Lineage Kinase Modulators

Docket No.: X15649

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

This response addresses the Office communication provided on May 13, 2008 wherein the present application was subjected to a restriction requirement.

Applicants make a provisional election and submit the following remarks.

The Office indicates that restriction is required under 35 U.S.C. 121 and 372. The following groups are provided by the Office:

Group I, Claims 5-13, drawn to compounds and compositions reading on Formula 1 claim 5.

Group II, Claim 14, drawn to a method of treating congestive heart failure limited in scope to one of the compounds of group I.

Applicants are required under 37 CFR § 1.143 to make a provisional election. Applicants provisionally elect Group I. Applicants also provisionally elect the species provided in Example 78, which is 2-fluoro-4-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]phenylamine Ditrifluoroacetic Acid, in the specification as filed. The provisional election encompasses Claims 5 through 13. Example 78 is within the scope of Claims 5 through 10 and 13.